Connecting scientific communities with trusted solutions, products and technology through peer-to-peer recommendations.
Global
Joined August 2010
- Tweets14.9K
- Following2.6K
- Followers10.7K
- Likes2.5K
Explore the technologies and expert insights helping researchers improve scalability, analytical confidence, and performance across the oligonucleotide workflow.
Read and explore the feature: eu1.hubs.ly/H0z0Fxd0
From atomic-scale ferroelectrics to beam-sensitive MOFs.
Prof. Knut M眉ller-Caspary of LMU Munich and Quantum Detectors explore how event-driven 4D-STEM can support quantitative analysis and low-dose imaging.
馃搮 Nov 11, 14:00 GMT
馃敆 eu1.hubs.ly/H0zs1T_0
Model-Informed Drug Development (MIDD) is helping clinical teams bring together safety, pharmacokinetic/pharmacodynamic, biomarker and efficacy data to optimize dose decisions earlier.
Register now to learn more: eu1.hubs.ly/H0z0BC_0
Explore how connected CMC knowledge can strengthen traceability, preserve scientific rationale and support Module 3 preparation: eu1.hubs.ly/H0ztLwb0
Great beer starts with consistency.
Join Dr. Jennifer Empey-Kohl and Rebecca A. Lucht from @thermofisher to explore how filtration and UV-Vis analysis can support clarity, quality and consistency across the brewing process.
Register now: eu1.hubs.ly/H0zdqKP0
Explore how industrial-scale protein production, flexible expression workflows and structured AI-ready data can help teams validate more candidates, accelerate DBTL cycles and unlock greater value from their discovery programs.
Last chance to register: eu1.hubs.ly/H0zhbGZ0
Explore our latest editorial feature for insights into electron microscopy, 4D-STEM, infrared and Raman microscopy, and the future of materials characterization.
Explore the feature: eu1.hubs.ly/H0z0CJn0
馃К What will it take to move MRD testing in liquid biopsy towards wider clinical adoption?
Join our #CLINICAL24 Forum to explore validation, reproducibility, standardization and best practice.
馃搮 Nov 5 | 16:00 GMT
馃敆eu1.hubs.ly/H0znHjh0
#MRD #LiquidBiopsy
The next chapter of cell line development is here.
Explore the advanced analytical technologies that are helping researchers generate deeper insight, scale with confidence and make more informed decisions across the workflow.
Download your free copy:
eu1.hubs.ly/H0z0CcM0
AI can design an antibody sequence, but can it produce a viable therapeutic candidate?
Brady Wu, PhD, of Biointron explores how rapid wet-lab validation and standardized data can strengthen AI-driven antibody discovery.
馃搮 Nov 19, 16:00 GMT
馃敆 eu1.hubs.ly/H0znMBn0
